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W e d e s c r ib e  th e  i s o la t io n  a n d  c h a r a c t e r i z a t io n  o f  tw o  
p e p t id e  to x in s  f ro m  C o n u s  e r m in e u s  v e n o m  ta r g e t e d  to  
n ic o t in ic  a c e ty lc h o lin e  r e c e p to r s  (n A C h R s). T h e  p e p t id e  
s t r u c tu r e s  h a v e  b e e n  c o n f i rm e d  b y  m a s s  s p e c t r o m e tr y  
a n d  c h e m ic a l  s y n th e s is .  I n  c o n t r a s t  to  th e  12-18  r e s id u e ,  
4  C y s -c o n ta in in g  a -c o n o to x in s ,  t h e  n e w  to x in s  h a v e  30 
r e s id u e s  a n d  6 C y s r e s id u e s .  T h e  to x in s , n a m e d  aA -cono - 
to x in s  E IV A  a n d  E IV B , b lo c k  b o th  T o rp e d o  a n d  m o u s e  
a 1 -c o n ta in in g  m u s c le  s u b ty p e  n A C h R s e x p re s s e d  in  X e- 
n o p u s  o o c y te s  a t  lo w  n a n o m o la r  c o n c e n t r a t io n s .  I n  c o n ­
t r a s t  to  a -b u n g a r o to x in ,  aA -E IV A  is  in a c t iv e  a t  a7 -co n - 
t a i n in g  n A C h R s e v e n  a t  m ic ro m o la r  c o n c e n t r a t io n s .  I n  
t h i s  r e g a r d ,  a A-EIVA is  s im i la r  to  t h e  p r e v io u s ly  d e ­
s c r ib e d  a -c o n o to x in s  (e.g. a -M I a n d  a -G I) w h ic h  a ls o  s e ­
le c t iv e ly  t a r g e t  a l -  v e r s u s  a 7 - c o n ta in in g  n A C h R s. H o w ­
e v e r ,  a -M I a n d  a -G I d is c r im in a te  b e tw e e n  th e  a!8 v e rsu s  
a /y  s u b u n i t  in t e r f a c e s  o f  th e  m o u s e  m u s c le  n A C h R  w i th  
10 ,000-fo ld  s e le c t iv i ty .  I n  c o n t r a s t ,  a A -c o n o to x in  EIV A  
b lo c k s  b o th  t h e  a /y  s i te  a n d  a/8  s i te  w i th  e q u a l ly  h ig h  
a f f in i ty  b u t  w i th  d i s t i n c t  k in e t ic s .  T h e  a A -c o n o to x in s  
t h u s  r e p r e s e n t  n o v e l p r o b e s  fo r  th e  a /y  a s  w e ll  a s  th e  a/8  
b in d in g  s i te s  o f  th e  n A C h R .
The carnivorous cone snails (genus Conus) comprise 500 
species th a t specialize on a variety of prey, including fish. 
There are —50-70  different fish-hunting Conus species which 
use venom as the prim ary weapon for immobilizing prey. Their 
venoms are extremely complex, and each Conus species has its 
own distinct complement of biologically active venom peptides. 
Nevertheless, all fish-hunting Conus venoms examined so far 
inhibit neurom uscular transm ission. In all cases, one major 
molecular target involved in  this inhibition is the nicotinic 
acetylcholine receptor (nAChR)1 a t the neurom uscular junc­
tion. Thus, all fish-hunting cone snail venoms appear to con­
ta in  a major venom peptide which, like the snake toxin a-bun- 
garotoxin, potently inhibits the postsynaptic nAChR by 
competitively blocking the acetylcholine (ACh) binding site.
Despite this common mechanism of action, there are consid­
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erable differences in the structures of the nAChR-antagonist 
peptides in the venoms of various fish-hunting cone snails. The 
major family of such peptides identified so far are the a-cono- 
toxins, which have been characterized from several species of 
Indo-Pacific fish-hunting cone snails (1). Recently, a peptide 
which is a competitive nAChR antagonist was purified and 
characterized from the E astern  Pacific piscivorous Conus spe­
cies, Conus purpurascens (the purple cone) (2). This peptide, 
aA-PIVA, has a disulfide framework entirely different from all 
other competitive nAChR antagonists from Conus. The peptide 
has three disulfide bonds instead of the two usually found in 
a-conotoxins. Furtherm ore, no obvious homology is detected be­
tween a- and aA-conotoxins when their sequences are aligned. 
Thus, the isolation of aA-PIVA suggests tha t there may be two 
major groups of competitive nicotinic antagonists in the venom 
of fish-hunting cone snails, the a- and the aA-conotoxins.
Perhaps the most closely related fish-hunting Conus species 
to C. purpurascens is the “tu rtle” cone, Conus ermineus, which 
is found throughout the tropical A tlantic (see Fig. 1). However, 
the first nAChR antagonist which we purified from C. ermineus 
venom was not homologous to aA-PIVA, but was instead a 
highly divergent a-conotoxin, a-EI (3). In this report, we dem­
onstrate th a t in addition to a-EI, the venom of C. ermineus 
contains two other nicotinic antagonists, which are aA-cono- 
toxins by virtue of the ir structural homology to aA-PIVA.
The discovery of these two peptides, aA-conotoxins EIVA and 
EIVB, expands the membership of the aA-conotoxin family and 
provides initial structure-function information which will be 
useful for studies using th is family of nicotinic antagonists. The 
three-dimensional structures of a-conotoxins GI (4) and PnIA 
are known (5), and th a t of the first aA-conotoxin was recently 
solved.2 Thus, the a- and aA-conotoxins now provide two sets of 
ligands of known three-dim ensional structure th a t can be used 
to probe the ligand binding sites of nAChRs in  vertebrate 
muscle. We dem onstrate here th a t the new aA-conotoxins have 
a selectivity profile which differs from both the a-conotoxins 
and a-bungarotoxin.
experimental procedures
Materials—Crude venom was obtained from milkings of C. ermineus 
kept in aquaria. The venom was stored at — 70 °C until used. Trifluoro- 
acetic acid (sequencing grade) was from Aldrich, acetonitrile (UV grade) 
was from Baxter, and [125]a-BTX was from NEN Life Science Products.
Venom Preparation—Individual milkings of C. ermineus venom (2, 3) 
collected from 10 snails were pooled (final volume 1.5 ml) and concen­
trated by lyophilization to 0.5 ml. The concentrate was mixed with 3 ml of 
0.1% trifluoroacetic acid just prior to application onto an HPLC column.
Goldfish Bioassay—Purification of the paralytic toxin was monitored 
by injecting fractions into goldfish as described previously (3).
2 Han, K. H., Hwang, K. J., Kim, S. K., Gray, W. R., Olivera, B. M., 
Rivier, J., and Shon, K. J. (1997) Biochemistry 36, 1669-1677.
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Fig. 1. C. erm ineus  and  o th e r Conus 
species. A, three specimens of the turtle 
cone, C. ermineus. B, the magus cone, C. 
magus. C, the purple cone, C. purpuras- 
cens. Note that from the shell characters, 
C. ermineus and C. purpurascens appear 
to be more closely related to each other 
than they are to C. m ^ u s . Bar = 1 cm.
HPLC Purification—The HPLC apparatus consisted of HPXL pumps 
and either a Dynamax model UVI or UV-DII detector (Rainin, Woburn, 
MA). All columns were also from Rainin. For isolation of peptide from 
venom and all subsequent purifications, buffer A consisted of 0.1% triflu­
oroacetic acid, and buffer B was 0.092% trifluoroacetic acid, 60% acetoni­
trile. Initial purification of aA-EIVA from milked venom was accom­
plished using a semipreparative C18 Vydac column (10 mm x 25 cm, 5-xm 
particle size), with a flow rate of5.0ml/min. Subsequent purification steps 
of aA-EIVA utilized an analytical C18 Microsorb or Vydac column 
(4.6 mm x 25 cm, 5-xm particle size) with a flow rate of 1.0 ml/min.
Sequence Analysis—Purified peptides were reduced by dithiothreitol, 
alkylated with 4-vinylpyridine, and HPLC-purified by previously de­
scribed methods (3). Sequencing was performed by an Applied Biosys­
tems Model 477A protein sequencer at the Protein/DNA Core Facility at 
the University of Utah Cancer Center.
Mass Spectrometry—Liquid secondary ionization mass spectra were 
measured using a Jeol HX110 (JEOL, Tokyo, Japan) double-focusing 
mass spectrometer operated at a 10-kV accelerating voltage and a 
nominal resolution of3000. The sample (in 0.1% aqueous trifluoroacetic 
acid and 25% acetonitrile) was mixed in a glycerol/3-nitrobenzyl alcohol 
matrix (1:1) and analyzed with an electric field/accelerating voltage 
scan over a narrow mass range. The mass accuracy of the HX110 
instrument under these conditions was typically better than 50 ppm.
Solid-phase Peptide Synthesis—Peptides were built on Rink amide 
resin using standard Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry 
on an ABI Model 431A peptide synthesizer. Coupling was carried out 
using equimolar amounts of amino acid derivative, dicyclohexylcarbo- 
diimide and 1-hydroxybenzotriazole. Amino acid side chains were pro­
tected as follows: Asp, trans-4-hydroxyproline (Hyp), Ser, Thr, Tyr 
(tert-butyl); Cys, His (trityl); Lys (tert-butoxycarbonyl) and Arg 
(pentamethylchromansulfonyl).
Linear peptides were released from resin (typically 100 mg), depro­
tected, and precipitated as detailed previously (7, 8). After precipita­
tion, pelleted peptides were readily soluble in 60% acetonitrile, 0.092% 
trifluoroacetic acid in H20. Peptides were purified by HPLC using Vydac 
C18 columns and eluted with buffers containing 0.1% trifluoroacetic 
acid in H20 (buffer A) and 60% acetonitrile, 0.092% trifluoroacetic acid 
in H20 (buffer B). Typically a linear gradient of 10-50% buffer B over 40 
min was used.
The linear peptides were first purified on a preparative HPLC col­
umn (22 mm x 25 cm, 10-xm particle size, 300-A pore size, flow 20 
ml/min). Following this, disulfide bonds were formed by oxidation with 
glutathione. Ten ml of 100 mM I2 in MeOH was added to 100 ml of 80 
mM glutathione in ^ 0  to make a stock solution of 40 mM reduced (GSH) 
and 20 mM oxidized (GSSG) glutathione. This solution was added to
HPLC effluent containing linear peptide to make a final concentration 
of 1 mM GSH, 0.5 mM GSSG. The pH was adjusted to 7.5 using dry Tris 
base or 0.75 M dibasic sodium phosphate buffer (pH 7.7), and the 
solution was incubated —20 h at room temperature. The resulting 
mixture of oxidized peptides potentially contained 15 isomers with 
different disulfide arrangements. The major product was purified on a 
preparative column followed by isocratic purification at 21% buffer B on 
a semipreparative column (10 mm x 25 cm, 5-xm particle size, 300-A 
pore size, flow 3 ml/min). Based on HPLC co-elution experiments and 
biological activity in goldfish, it was determined that both aA-EIVA and 
aA-EIVB are the major products under the oxidation conditions used.
Electrophysiology—cRNA encoding nAChR subunits was prepared 
and injected into Xenopus oocytes as described previously (8). Oocytes 
were injected 1-2 days after harvesting and used for voltage clamp 
recording 1-7 days after injection. “a1^1y” and “a1^18” receptors were 
expressed by omitting cRNA for either the 8 or y subunit, respectively, 
from the usual a1fiy8 cRNAinjection mixture used to express wild-type 
muscle receptors (9, 10).
Voltage clamp recording was done as described previously (8). 
Briefly, oocytes were clamped at —70 mV with a two-electrode system 
and perfused with ND96 containing 1 /xM atropine (to block any endog­
enous muscarinic acetylcholine receptors). ND96 consists of 96 mM 
NaCl, 2.0 mM KCl, 1.8 mM CaCl2, 1.0 mM MgCl2, 5 mM Hepes (pH 
7.1-7.5). ACh-gated currents were elicited with 1-s pulses of 10 xM ACh 
(for Torpedo and mouse a1^1y and a 1fi18 nAChRs), 1 xM ACh (for 
wild-type muscle nAChRs), 300 xM (for a4^2, a3^2, and a3^4 nAChRs), 
and 1 mM ACh (for a l nAChRs), applied at a frequency of 1/min, except 
for a4^2 receptors which were pulsed every 3 min to avoid desensitiza­
tion. To elicit currents sufficient for recording a 10-fold higher concen­
tration of ACh was necessary with a1^1y and a1^18 compared with 
wild-type nAChRs. When both ACh concentrations were tested on the 
wild-type muscle receptors the same toxin affinity was observed (data 
not shown). These results were expected given the short duration of 
ACh exposure during test pulses and the comparatively slow dissocia­
tion rate  of the toxin. The ACh applied was approximately the lowest 
concentration required to elicit maximal current responses at each 
receptor subtype. For the muscle and Torpedo receptors, however, a 
submaximal concentration was chosen to allow the typically large cur­
rent reponses to be voltage-clamped.
Toxins were applied in ND96 containing 1 xM atropine and 0.1 mg/ml 
bovine serum albumin. Exposure to each concentration of aA-EIVA or 
aA-EIVB was continued until the peak amplitudes of the ACh-gated 
currents reached a steady state. The average peak amplitude of at least 
four control responses recorded in the absence of toxin was used to 
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tional response.” After application of toxin, the perfusion medium was 
switched back to ND96 with atropine. All kinetic and dose-response 
curves were generated using Prism software (GraphPad Software Inc., 
San Diego, CA). Dose-response curves were fit to the equation: fraction 
response = 1/(1 + ([toxin]/IC50) H) where nH is the Hill coefficient.
Curve-fitting o f Toxin Kinetics—It is assumed that the toxin (T) 
reversibly binds to its receptor site (S ) according to the scheme,
b 't,on
T + S N  TS
k off
Scheme 1
with forward and reverse rate constants kon and koff, respectively. It is 
also assumed that the amount of toxin greatly exceeds the number of 
sites, and thus the forward reaction follows pseudo-first order kinetics. 
We define p(t) as the probability that a site is occupied by toxin at time 
t  and q(t) as the probability that the site is unoccupied; so q(t) = (1 — 
p(t). If the system is initially at equilibrium, then when the concentra­
tion of toxin is perturbed to a new concentration [T], the toxin occu­
pancy of the site will relax to a new equilibrium value exponentially 
with a rate constant k = (kon[T] + koff) (see e.g. Ref. 6). Thus, p  will 
follow a time course from its initial value p(0) to its new equilibrium 
value p(») according to the equation
p(t) = [p(0) -  p(^y\e k + p H  
which rearranged yields











1 + k on[T\
It is also assumed that each receptor has N  independent toxin- 
binding sites, and that occupancy of a single site is sufficient to inacti­
vate the receptor. Then the probability that a receptor is active would be 
given by the probability that none of the sites on the receptor is occu­
pied, and this in turn is given by the product of the probabilities of each 
site being unoccupied; in other words, the fraction of receptors that are 
active, FA(t), is given by qN(t) if the binding sites are kinetically equiv­
alent. If sites are not equivalent, FA(t) is the product of probabilities
FA(t) = n  qi(t) (Eq. 5)
FA(t) = n  Qi(t) = q1(t) ■ q2(t) (Eq. 9)
with qt(t) specified by Equation 8 using the respective kon and koff for 
each site.
Note that when the initial concentration oftoxin is zero (i.e. [T0] = 0), 
then Equation 8 reduces to
q(t) = 1 -
— e — (kon[T\+koff)t1 -  e
1 + kon[T\
(Eq. 10)
Conversely, when the toxin is washed out (i.e. [T ] = 0) following equil­





Note that since p(0) andp(») are equilibrium values before and after the 
toxin concentration was perturbed (say from [T0] to [T]), their values 
are given by the well-known relationship described by a rectangular 
hyperbola or binding isotherm, that is
Our experiments monitored FA(t) with pulses of ACh that produced 
brief responses (time to peak —1 s). Thus, the receptors are exposed to 
ACh only for a relatively short time compared with the off-kinetics of 
the toxin (1/koff) —1 min), and ACh has only minimal opportunity to 
displace toxin from the receptors. We therefore assumed that the pulses 
of ACh did not perturb the binding of toxin to receptor. To simplify the 
curve-fitting of toxin wash-out, the binding isotherm p (0), used to de­
scribe the initial conditions in Equation 11, was replaced by a variable, 
1 — ymin, and final conditions were described by a second variable, ym;ax, 
yielding the equationy  = (ymax — [1 — ymiJe—kofft)N. The values for koff 
were then used in Equation 10 to fit toxin wash-in curves and calculate 
k on values.
Inhibition o f 125I-a-BTX Binding to Nicotinic Receptors on Intact 
BC3H-1 Cells—Binding methods were as described previously (3). 
Briefly, BC3H-1 cells were incubated in 250 ^l of assay buffer (140 mM 
KCl, 25 mM HEPES, 5.4 mM NaCl, 1.8 mM CaC^, 1.7 mM MgSO4, 0.06 
mg/ml bovine serum albumin, pH 7.4) with or without aA-conotoxin 
EIVA. 125I-a-BTX (10 ^l, final concentration 20 nM) was then added, 
and the reaction was allowed to incubate for an additional 15 min. Cells 
were then washed twice with 2.0 ml of assay buffer to remove unbound 
ligands, and receptor-bound 125I-a-BTX was removed from the wells 
with two 0.5-ml washes of 1% Triton X-100 in water and counted in a y 
counter. Nonspecific binding was determined with cells previously ex­
posed to 100 nM a-BTX for 30 min. The total density of 125I-a-BTX 
binding sites was determined from a 60-min incubation in the absence 
of competing drug. Approximately 60-70% of the total specific 125I-a- 
BTX binding sites were labeled by 125I-BTX during the 15 min of the 
assays. All assays were performed at room temperature in triplicate.
RESULTS
Purification—Crude venom from C. ermineus obtained by 
milking snails was fractionated by HPLC. The elution pattern  
of two of the peptides paralytic to fish are shown in Fig. 2. 
These venom fractions were subfractionated until the peptides 
were purified to homogeneity. Disulfide bridges were reduced, 
and cysteines were alkylated prior to sequencing. Their amino 
acid sequences are as follows.
where qt represents the probability that the ith  site is unoccupied. 
Substituting the relationship in Equation 2 for (1 — p (t)) gives the 
following term for q(t)
q(t) = (1 -  p{0>)e— -  p H [1 -  e~kt\) 
which rearranged yields
q(t) = (1 + [p H  -  p(0)\e—kt -  p(<»))
(Eq. 6)
(Eq. 7)
When k, p(0), and p(“ ) are replaced with their expanded versions given 
above, this yields
q(t) = 1 +
1 1
1 koff 1 koff








Thus, for nAChRs with two nonequivalent binding sites, where occupa­
tion of either site is sufficient to block receptor function, the fraction of 
active receptors is given by
These sequences were confirmed by mass spectrometry (MH + 
= 3095.2 and 3099.1); these values are consistent with the pep­
tides amidated a t their C term ini and with all of the Cys residues 
in disulfide linkages (calculated mass 3095.2 and 3099.2).
Chemical Synthesis o f the Purified Peptides—Based on the 
putative sequences, the two peptides were synthesized by solid- 
sta te methods as described under “Experim ental Procedures.” 
The linear peptides were oxidized to form disulfide linkages. 
When air oxidation was used, the m aterial corresponding to 
native peptide was not formed in high yield (data not shown). 
However, when glutathione oxidation was performed the major 

































Fig. 2. P u rifica tio n  of aA -conotoxins EIVA and  EIVB from  C. 
erm ineus  venom . Buffer A = 0.1% trifluoroacetic acid; buffer B = 
0.092% trifluoroacetic acid, 60% acetonitrile. Milked venom (see text) 
was applied to a semipreparative C18 Vydac column. The gradient 
program was 0-15% B for 5 min, 15-40% B for 74 min, 40-75% B for
3 min, followed by 75-100% B for 14 min; flow rate was 5 ml/min. The 
major components of the peptide absorbances indicated with closed 
arrows correspond to a-conotoxins EIVA and EIVB, respectively (elut­
ing at 31.1 min and 39.6 min). These materials were purified to homo­
geneity using the semipreparative Vydac column described above with 
a gradient program beginning at 5-30% B for 75 min. Each of the major 
peaks was then subsequently run on an analytic Microsorb C18 column 
and eluted with a gradient program of 4-30% B for 75 min and flow rate 
of 1 ml/min (data not shown). The peptide absorbance indicated by the 
open arrow at 51.7 min corresponds to a-conotoxin EI, the isolation of 
which has been described previously (3).
scribed below (Fig. 3, A  and B). These major products were 
purified to homogeneity. The cleavage of 100 mg of resin  typi­
cally yielded 5-10 mg of biologically active peptide product.
W hen co-injected on HPLC the purified, chemically synthe­
sized peptides co-eluted w ith the corresponding native peptide, 
as shown in Fig. 3, C  and D . Mass spectrometric analysis 
showed th a t the molecular masses of synthetic peptides are 
consistent w ith the predicted sequences (MH+ = 3095.2 and 
3099.2; calculated mass 3095.19 and 3099.18). Furtherm ore, 
the paralytic activity of the synthetic peptides was quan tita ­
tively the same as th a t of the native peptides when injected 
into goldfish (data not shown). Thus, under glutathione oxida­
tion conditions these peptides appear to form the disulfide 
linkages necessary to confer biological activity. Due to the 
lim ited availability of natu ra l peptides, all subsequent experi­
m ents were performed w ith synthetic m aterial.
M echanism o f Action o f the Purified Peptides—The peptide 
sequences have considerable homology w ith th a t of aA-PIVA, 
which has been shown to be an antagonist of the nAChR a t the 
neurom uscular junction. Given the strong homology between 
the peptides from C. purpurascens and C. ermineus, our initial 
hypothesis was th a t the C. ermineus peptides cause paralysis 
because they are also nAChR antagonists. To directly assess 
the functional effects of these peptides, electrophysiological 
experiments were carried out w ith cloned skeletal muscle 
nAChRs expressed in  Xenopus oocytes. Fig. 4A  shows the re ­
sults obtained when the peptides were tested on oocytes ex­
pressing Torpedo nAChRs. It is clear th a t both peptides are 
potent inhibitors of ACh-gated currents under these conditions, 
w ith nearly identical IC50 values. Given these results and the 
structural homology to aA-PIVA, we designate these peptides 
as aA-conotoxins EIVA and EIVB.
a -MI is typical of many a-conotoxins from Indo-Pacific fish- 
hunting  Conus venoms in th a t it  prefers the a /8 over the a/y 
interface of the mouse muscle nAChR (11, 12) and the a/y  over 
the a/8 (11-13) interface in the Torpedo electric organ nAChR. 
We compared the affinity of aA-EIVA for each interface by 
using receptors expressed in oocytes in which only cRNA for the
Fig. 3. C hem ical syn thesis of aA-EIVA and  aA-EIVB. Disulfide 
bonds were formed in linear peptides by oxidation with glutathione (1 
mM reduced, 0.5 mM oxidized, pH 7.5) for 24 h, yielding mixtures of 
isomers as shown by HPLC chromatograms in A  for aA-EIVA and in B 
for aA-EIVB. The major peak in each reaction mixture was purified to 
homogeneity and found to co-elute using HPLC when co-injected with 
the natural peptides as shown in C for aA-EIVA and in D for aA-EIVB. 
HPLC-run conditions are detailed under Peptide Synthesis under “Ex­
perimental Procedures.” Absorbance was measured at 220 nm.
mouse muscle a 1, 01 , 8 or a 1, 01 , y  subunits was injected, 
forcing the formation of receptors w ith only a/8 or a/y in te r­
faces, respectively (9, 10). As a control, 10 nM a-bungarotoxin 
was tested on these receptors in duplicate experiments. a-Bun- 
garotoxin blocked —85% of the a1018 receptor response and 
—92% of the a101y receptor response after 15 min of exposure 
to toxin (data not shown). Fig. 4B  shows the potency of aA- 
EIVA when tested on a1018y nAChRs, term ed wild-type recep­
tors, and on the subunit-deficient variations of this receptor. 
These results differ m arkedly from those previously shown for 
a-MI, which prefers a1018 receptors w ith a discrimination 
index of 104 (14). The IC50 values of aA-EIVA for wild-type, 
a1018, and a101y receptors are almost identical. Thus, it ap­
pears th a t both the a  1/8 and a 1/y interfaces are high affinity 
targets for aA-EIVA.
Toxin Kinetics—The wild-type mouse muscle nAChR is 
known to contain ACh binding sites a t the a1/8 and a1/y sub­
un it interfaces (15), both of which m ust be occupied by agonist 
to activate the receptor. Receptors containing only a 1018 or 
a 101y subunits have also been shown to contain two agonist 























Fig. 4. D ose-response curves fo r b lock of m uscle nAChRs ex ­
p ressed  in  X enopus oocytes by  oA-EIVA and  oA-EIVB. A, block of 
Torpedo nAChRs by aA-EIVA (open triangles, IC50 17 nM) and aA-EIVB 
(closed triangles, IC50 18 nM). B, aA-EIVA block of mouse wild-type 
(circles, IC50 11 nM), a1|81y (open squares, IC50 11 nM), and a1|818 
nAChRs (closed squares, IC50 15 nM). Error bars are the S.E. (n = 3-7).
w ith respect to competitive antagonist binding (10). To calcu­
late the ra te  constants kon and koff for the interaction of aA- 
EIVA with a1^1S and a1^1y receptors, we used the model w ith 
two equivalent competitive antagonist binding sites (at the two 
a 1/8 or two a 1/y interfaces) in which binding to either site is 
sufficient to inhibit receptor function (10, 16). Since the wild- 
type receptor contains both an a 1/8 and an a 1/y toxin binding 
site, the receptor should exhibit kinetics consistent w ith both 
sites. In fact, th is is w hat was observed. Fig. 5 shows the time 
course of aA-EIVA block and recovery from block on a1^1S, 
a1^1y, and wild-type mouse muscle nAChRs. The param eters 
k on, k off, and Kd for these receptors are summ arized in  Table I. 
As shown in Fig. 5, use of the kinetic values calculated from 
a 1^ 1S and a 1^ 1y receptors provides a good description of block 
and recovery from block by aA-EIVA on the wild-type receptor.
The observed rates of both block and recovery from block by 
toxin was more rapid for a1^1S versus a1^1y receptors. For the 
wild-type receptor, the observed ra te  of toxin block was rela­
tively fast, like th a t of the a1^1S receptor. In contrast, the rate 
of recovery from toxin block for wild-type receptor was slower, 
comparable to th a t observed for the a1^1y receptor. Thus, the 
kinetics of block of wild-type receptor appear to be dictated 
prim arily by the faster toxin association ra te  of the a 1/8 site, 
while the ra te  of recovery of receptor function following toxin 
wash-out is prim arily influenced by the slower dissociation rate 
of the a1/y site. This is the expected result if binding of toxin to 
a single agonist site is sufficient to block receptor function.
To investigate further the target specificity of aA-EIVA, we 
tested its  activity on the a7 subtype of neuronal nAChRs. No
Fig. 5. K inetics of block by  oA-EIVA of m ouse m uscle nAChRs 
expressed  in  X enopus oocytes. A 25 nM toxin solution was applied by 
perfusion at 1 ml/min, and currents were measured by pulsing with 
ACh at 1-min intervals. After an equilibrium blockade was achieved, 
toxin was washed out by perfusion of ND96 buffer solution. A , time 
course of block by toxin on wild-type (circles), a1|81y (open squares, kon 
= 0.94 X 107 ± 0.03 M—1 min—1) and a1|818 (closed squares, kon = 3.37 X 
107 ± 0.10 M—1 min—1) nAChRs. The dotted line shows the curve fit to 
wild-type data by a model of two unequal binding sites using the koff 
values for sites on the a1|81y and a1|818 nAChRs. Note that the kon 
values for this curve, 1.65 X 107 ± 0.36 and 3.07 X 107 ± 0.91 M—1 
min—1, approximate those for the a1|81y and a1|818 receptors, respec­
tively, with corresponding values within a 95% confidence interval of 
each other. B, recovery from block of wild-type (circles), a1|81y (open 
squares, koff = 0.30 ± 0.07 min—1), and a1|818 (closed squares, koff =
1.26 ± 0.19 min—1) nAChRs. A theoretical curve for the wild-type 
receptor (dotted line) was generated by a two-site binding model using 
koff values for binding sites on the a1|818 and a1fi1y receptors (R2 = 
0.82). All curves were fit as described under “Experimental Proce­
dures.” Error bars are the S.E. (a1|818, n = 2; a1fi1y, n = 3; wild-type, 
n = 5).
detectable block of ACh-gated currents was observed in  a7- 
expressing oocytes perfused w ith 1 xM aA-EIVA or upon expo­
sure to 60 xM toxin in a static bath  (data not shown). We also 
tested aA-EIVA on oocytes expressing a4^2, a3^2, or a3^4 
nAChRs. 1 xM toxin (applied by perfusion) blocked a4^2 recep­
tors —25% bu t failed to block a3fi2 or a3^4 nAChRs (n = 3).
To assess the mechanism of aA-EIVA action, binding exper­
im ents w ith radiolabeled a -bungarotoxin and muscle nAChR- 
expressing BC3H -1 cells were carried out. The results of these 
experiments are shown in Fig. 6. In this assay, the aA-EIVA 
displaced all specific binding of 125I-a-bungarotoxin to BC3H-1 
cells, consistent w ith the toxin being a competitive antagonist 
of the nAChR. In addition, the data are best fit by a dose- 
response curve for a single-site model. This is consistent w ith 
the oocyte studies indicating th a t aA-EIVA has nearly equal 
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Table I
Association and dissociation constants o f aA-EIVA for nAChRs 














M-1min-1 min-1 nM nM nM
a1$18 3.37 1.26 37 15 15
a1fi1y 0.94 0.30 32 13 11
(kof k on) is a measure of toxin affinity for a singlea The calculated Kd 
binding site.
b The IC50 measures the functional block of receptor by toxin, pre­
sumably through binding at either of two pharmacologically equivalent 
binding sites present on a single receptor. The predicted IC50 was 
obtained from the calculated Kd using the equation: fractional re­
sponse = 1/(1 + [toxin]/Kd)2. When [toxin] = IC50, fractional response = 
0.5, and this equation reduces to: IC50 = 0.414 • Kd.
Table II
Subunit selectivity of toxin binding in mammalian nAChRs
a1/8 a1/y al
I-M-a + - -
aA-EIVA + + -
a-Bungarotoxin + + +
DISCUSSION
The data presented above dem onstrate the presence of two 
peptides from the venom of C. ermineus, aA-EIVA and aA- 
EIVB, which are competitive antagonists of nAChRs. aA-Cono- 
toxin EIVA was examined in detail and has several notable 
functional features. First, unlike a-bungarotoxin, which has 
subnanomolar affinity for a7 nAChRs (17, 18), aA-EIVA does 
not block these receptors even a t micromolar concentrations. In 
this regard, aA-EIVA behaves like a-conotoxins MI and GI, 
which potently target a1-containing, bu t not a7, nAChRs (18). 
Thus, Conus has evolved two independent structures th a t dis­
crim inate between a1 versus a7 receptors. However, like 
a-bungarotoxin, aA-EIVA has high affinity for both the a/8 and 
a/y sites of the muscle subtype of nAChR as shown by both 
electrophysiological and radioligand binding experiments (al­
though the peptide association and dissociation rates differ for 
each site). In contrast, a -conotoxins MI and GI are highly 
selective for the mouse muscle a/8 versus a/y site (104-fold 
discrimination). These divergent specificities are summ arized 
in  Table II. The structural basis for these differences in ligand 
affinity is presently under investigation. In addition, a struc­
tu ra l determ ination of aA-EIVA is almost complete.3
Sine et al. (14) have identified th ree critical residues in the 8 
nAChR subunit (Ser-36, Tyr-113, and Ile-178) which confer 
upon a-MI high a/8 versus a/y  affinity (14). When residues in 
the homologous positions of the y  subunit were m utated  to 
contain these amino acids, m utan t a1j61y receptors had a high 
affinity for a-MI. The results of the present study suggest th a t 
aA-EIVA recognizes a t least a partially  different set of receptor 
residues from those recognized by a-MI, since aA-EIVA has a 
high affinity for both the a/8 and a/y sites. Although it is 
possible th a t all of the contact residues for aA-EIVA binding 
are in the a subunit, it appears from the differences in kinetics 
of toxin binding to a1j618 versus a1j61y receptors th a t the 8 and 
y subunits also influence binding.
a-Bungarotoxin binds w ith high affinity and slow reversibil­
ity  to both a/8 and a/y sites in the mouse muscle nAChR (19, 
20). Our experiments w ith radiolabeled a-bungarotoxin indi­
cate th a t aA-EIVA can block all specific binding of a-bungaro- 
toxin to BC3H-1 cells in a concentration-dependent m anner. 
The resulting dose-response curve is best fit by a single-site
3 K.-H. Han, K. J. Hwang, S. K. Kim, W. R. Gray, B. M. Olivera, J. 
Rivier, and K. J. Shon, unpublished results.
Fig. 6. In h ib ition  of 125I-a-BTX b ind ing  to n ico tin ic  recep to rs  
on BC3H-1 cells by aA-EIVA. The data shown are the mean ± S.E. of 
four independent experiments. The IC50 and nH were found to be 150 ± 
10 nM and 0.85 ± 0.02, respectively. The data are fit best by a single-site 
competition model with a variable Hill coefficient (solid line) as deter­
mined by statistical comparison between a single-site and a two-site 
competition model (p < 0.001).
model. These results are consistent w ith those from oocyte 
experiments which indicate th a t aA-EIVA binds w ith nearly 
equal affinity a t both an a/8 and a/y site. However, aA-EIVA 
blocked a-bungarotoxin binding to mouse BC3H-1 cells w ith an 
IC50 th a t was approxim ately 10-fold higher than  th a t observed 
for aA-EIVA block of mouse muscle nAChRs expressed in oo­
cytes. This difference is partly  explained by the fact th a t aA- 
EIVA m ust occupy two binding sites on each receptor to com­
pletely block a-bungarotoxin binding, while block of functional 
response can occur by occupation of either site alone. This 
should result in an 2.4-fold difference between the functional 
block described by the IC50 in oocyte experim ents and the IC50 
observed by competition binding (see legend to Table I). F ur­
ther differences in IC50 values between the experiments may be 
due to kinetic factors. In oocyte experiments, the binding equi­
librium  of aA-EIVA should not be affected appreciably by the 
b rief applications (1-s pulses) of ACh due to the comparatively 
slow koff of the toxin. In contrast, aA-EIVA has a much faster 
k off th an  a-bungarotoxin. During the 15-min co-incubation of 
these toxins in the binding experiments, occupation of free 
binding sites by the essentially irreversible binding of a-bun- 
garotoxin would be expected to shift the resu ltan t dose-re- 
sponse curve of aA-EIVA toward a higher apparent IC50.
aA-EIVA and aA-EIVB have sim ilar sequences and may 
represent polymorphism in the C. ermineus population. Al­
though these peptides are specifically targeted to the skeletal 
muscle subtype of the nAChR, they are broadly active in ver­
tebrate systems; we dem onstrated directly th a t they are antag­
onists when tested against skeletal muscle nAChRs in both 
elasmobranchs (Torpedo electroplax) and mammals (mouse).
In all fish-hunting cone snails, there appears to be a t least 
one major peptide which is a competitive antagonist of skeletal 
muscle nAChRs; a sum m ary of all such peptides from piscivo­
rous Conus venoms which have been described thus far are 
shown in Table III. It is clear from the table th a t these peptides 
fall into two quite distinct families, the a-conotoxins and the 
aA-conotoxins. Before this report, only one aA-conotoxin had 
been described, aA-PVIA from C. purpurascens (2). The two 
peptides described here clearly exhibit homology to aA-PVIA, 
although they diverge substantially  in sequence. As we noted 
previously, C. purpurascens and C. ermineus are the only fish- 
hunting cone snails known outside the Indo-Pacific region, and 
it is likely th a t they have long been isolated geographically 
from the major series of Indo-Pacific fish-hunting Conus. In all 
of the Indo-Pacific piscivorous species, an  a -conotoxin is the 
major skeletal muscle nAChR antagonist.
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Table III
Competitive skeletal muscle nAChR antagonists from venoms o f fish-hunting Conus
Sequence Conus species Ref.
aA-EIVA gccgpyonaachocgckvgrooycdrosgg* C. ermineus This work
aA-EIVB gccgkyonaachocgctvgrooycdrosgg* C. ermineus This work
aA-PIVA gccgsyonaachocsckdrosycgq-5 C. purpurascens (2)
a-MI grcchpacgknysc* C. magus (22, 23)
a-GI eccnpacgrhysc* C. geographus (24)
a-GIA eccnpacgrhyscgk* C. geographus (24)
a-GII ecchpacgkhfsc* C. geographus (24)
a-SIA ycchpacgknfdc* C. striatus (25)
a-SI iccn pacgpk ysc* C. striatus (26)
a-SII gcccnpacgpnygcgtscs^ C. striatus (27)
a-EI rdoccyhptcnm snpqic5 C. ermineus (3)
a Amidated C terminus; o , hydroxyproline. 
b Free C terminus.
so far to contain both a major a-conotoxin as well as aA- 
conotoxins. The a-conotoxin described from C. ermineus, a-EI, 
is also divergent from those found in piscivorous Indo-Pacific 
species. However, it rem ains puzzling why th is Conus species 
has both classes of competitive antagonists. At th is time, we 
cannot distinguish between several hypotheses. Individual 
specimens of C. ermineus may express only the a- or only the 
aA-conotoxins a t any one tim e, such as a seasonal variation in 
expression, or there may be polymorphism in the population. 
Since only pooled venom from m any snails has been analyzed 
so far, we cannot eliminate these possibilities directly. A lter­
natively, it is possible th a t the a - and aA-peptides have in trin ­
sically different functional targets, and th a t w ithin an individ­
ual snail venom, both classes of peptides are expressed. For 
example, if the peptides have different efficacies a t different 
types of teleost neurom uscular junctions or if the different fish 
prey of C. ermineus diverge significantly in  the ir neurom uscu­
lar junction nAChRs, then it may be advantageous for the 
predator to have both conotoxin classes in its venom.
Conus species produce a rem arkable variety of nicotinic re­
ceptor antagonists. The a-conotoxins w ith a “4/7” spacing (con­
taining sequences of 4 and 7 consecutive non-cysteine amino
acids, i.e.. CC— C.........C) are widely found in worm- and snail-
hunting Conus species as well as some fish-hunting species (see 
Table III and Refs. 8 and 21).4 These toxins target muscle 
nAChRs as well as neuronal subtypes and may represent the 
ancestral stem  group of nAChR antagonists. The sm aller pep­
tides w ith “3/5” spacing, produced by Indo-Pacific species, and 
the larger aA-conotoxins may represent separate evolutionary 
lineages for targeting  vertebrate muscle nAChRs.
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